Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD): This Biotech Leader Is Poised to Outperform

Sofosbuvir was acquired with the purchase of Pharmasset for $11 billion last year, and it has already proven itself in four Phase III studies. The drug is showing impressive response, and it has lower side effects than competing alternatives. Gilead expects to launch sofosbuvir in the US during the first quarter of 2014, and a European launch planned in the second quarter of next year if things go as expected.

Other companies are trying to enter the hepatitis-C market too: Johnson & Johnson (NYSE:JNJ) may even be ahead of Gilead with its simeprevir drug for oral hepatitis-C treatment. The pharmaceutical giant got priority review acceptance from the FDA for simeprevir on May 13, while Gilead´s drug got approved for priority review in June 7.

It’s worth considering that the combination between Gilead Sciences, Inc. (NASDAQ:GILD)´s safosbuvir and Johnson & Johnson (NYSE:JNJ)´s simeprevir has shown very promising results in the experimental phase, so I wouldn’t discard a scenario in which both drugs are used in conjunction, especially when it comes to patients with severe conditions.

AbbVie Inc (NYSE:ABBV) is another serious contender in that competition; the company´s hepatitis-C drug combination received the breakthrough therapy designation from the FDA, and it has proven to be notoriously effective in trials. Abbvie´s head of drug development, Scott Brun, recently told Bloomberg that he believes the company has “a very good shot at being first” in the race versus Gilead and Johnson & Johnson (NYSE:JNJ).

Timing is relevant, but it’s not the only important thing to consider. AbbVie Inc (NYSE:ABBV)´s treatment is a combination of four different pills with their own time schedules, and this could be a big disadvantage when it comes to patient compliance and costs.

All in all, even considering competitive threats, it looks like Gilead Sciences, Inc. (NASDAQ:GILD) is well positioned to profit substantially from its coming hepatitis-C drug sofosbuvir.

Bottom line

Gilead has an undisputed leadership position in HIV treatments, and the company´s pipeline looks quite exciting, especially when it comes to its huge opportunity in hepatitis-C dr. There is always considerable risk when investing in the biotech sector, but in the case of Gilead, those risks looks more than compensated by the company´s upside potential.

The article This Biotech Leader Is Poised to Outperform originally appeared on Fool.com and is written by Andrés Cardenal.

Andrés Cardenal has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences (NASDAQ:GILD) and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.